Telmisartan for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Telmisartan, a prescription blood pressure medication, draws longevity interest for partial effects on sugar and fat handling. Evidence is strongest for lowering raised blood pressure and urine protein. It protected high-risk people about as well as an older heart-protective drug, but not clearly beyond inactive treatment. Metabolic gains are small. Main risks are dizziness, high blood potassium, a dip in kidney filtering and serious harm to an unborn baby. (Full Review)

Protocol

Conventional hypertension dosing
40 mg once daily
Response dose-related over 20–80 mg; larger doses add little
Cardiovascular risk-reduction dosing
80 mg once daily
Dose used in ONTARGET and TRANSCEND; lower doses untested for outcomes
Single versus split dose
Single daily dose
Maintains effect across 24 hours; with or without food
Time to effect
Blood pressure lowering
Within 2 weeks
Most of the lowering appears
Peak blood pressure effect
About 4 weeks
Maximal effect, when dose is reassessed
Albuminuria and glucose
Months
Changes in trials measured over months

Benefits

Contraindications
  • Pregnancy, especially second and third trimesters
  • Breastfeeding
  • Biliary obstruction, cholestasis or severe hepatic impairment
  • Known hypersensitivity or angioedema to telmisartan
  • Diabetes, or eGFR below 60 mL/min/1.73 m², in people taking aliskiren
  • Baseline serum potassium above 5.0 mmol/L
Key Interactions
  • ACE inhibitors (ramipril, lisinopril): more hypotension, fainting and kidney dysfunction, no added benefit
  • Digoxin: raised digoxin levels, risking toxicity
  • Rosuvastatin: raised rosuvastatin exposure
  • Lithium: raised lithium levels with toxicity
  • NSAIDs, including COX-2 inhibitors (ibuprofen, celecoxib), prescription or over-the-counter: possible acute kidney injury in older, volume-depleted or kidney-impaired people; weaker blood pressure lowering
  • Potassium supplements, potassium-sparing diuretics (spironolactone) and potassium salt substitutes: additive hyperkalemia
  • High-dose diuretics (furosemide): symptomatic hypotension at initiation
  • Metformin: lower metformin exposure
  • CYP2C19 substrates (clopidogrel, omeprazole): levels and response could change
  • Trimethoprim (including co-trimoxazole): hyperkalemia
  • PDE5 inhibitors (sildenafil): additive blood pressure lowering
  • Insulin and sulfonylureas (such as glipizide): hypoglycemia in diabetic patients
  • Alpha-blockers (doxazosin): additive blood pressure lowering with a pressure drop on standing
  • Alcohol: aggravated blood pressure drop on standing, with dizziness
  • Mycophenolate mofetil: lower mycophenolic acid exposure, risking weaker immunosuppression
Theoretical (inferred from mechanism)
  • Blood-pressure-lowering supplements (beetroot nitrate, garlic extract): additive blood pressure lowering may cause dizziness
  • SGLT2 inhibitors (empagliflozin): first-dose hypotension and creatinine rise
  • Licorice (glycyrrhizin) and decongestants (pseudoephedrine): blunted blood pressure control

Risk & Side Effects

  • High:
  • Medium: Symptomatic hypotension, decline in kidney function, hyperkalemia, common label-listed adverse events, sepsis
  • Low: Angioedema, fetal toxicity, cancer, sprue-like enteropathy, rare post-marketing reactions
  • Speculative:

Monitoring

Marker Target Why
Blood pressure (home, seated and standing) Below 130/80 mmHg Expected to change; hypotension safety check
Serum potassium 4.0–5.0 mmol/L Safety check
Serum creatinine and eGFR Creatinine about 0.6–1.3 mg/dL; eGFR tracked against own baseline Safety check
UACR Below 30 mg/g Expected to fall
Fasting glucose and HbA1c Fasting glucose below 100 mg/dL; HbA1c below 5.7% Expected to change modestly
Digoxin or lithium level (if taking) Not specified in the ER Drug-level check
Pregnancy test (women who could become pregnant) Not specified in the ER Baseline check

Cadence: Potassium and creatinine 1–2 weeks after starting or each dose increase; blood pressure daily for the first 2–4 weeks; potassium, creatinine, eGFR and UACR at 3 months and every 6–12 months; HbA1c and fasting glucose every 6–12 months; sooner after illness, dehydration or new interacting drugs

Qualitative Assessment

  • Dizziness or lightheadedness on standing, especially in the morning or after exercise
  • Energy levels and exercise tolerance compared with before starting
  • New persistent cough, facial or lip swelling, or chronic diarrhea
  • Muscle pain or weakness, dark urine, or yellowing of the skin
  • Sleep quality and nighttime awakenings